BioCorRx annual operating margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioCorRx's operating margin was −606.04% for fiscal 2025.
View full BioCorRx company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −606.04% | +66223.77 pp |
| 2024 | 2024-12-31 | −66,829.81% | −62581.50 pp |
| 2023 | 2023-12-31 | −4,248.31% | −2051.36 pp |
| 2022 | 2022-12-31 | −2,196.96% | +9217.75 pp |
| 2021 | 2021-12-31 | −11,414.71% | −5304.84 pp |
| 2020 | 2020-12-31 | −6,109.86% | −3795.16 pp |
| 2019 | 2019-12-31 | −2,314.70% | −1086.52 pp |
| 2018 | 2018-12-31 | −1,228.18% | −788.35 pp |
| 2017 | 2017-12-31 | −439.84% | −128.91 pp |
| 2016 | 2016-12-31 | −310.93% | +242.51 pp |
| 2015 | 2015-12-31 | −553.45% | −292.75 pp |
| 2014 | 2014-12-31 | −260.70% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,665.95% | −970.66 pp |
| Q1 2026 | 2026-03-31 | −445.61% | +33407.35 pp |
| Q3 2025 | 2025-09-30 | −306.28% | +26453.16 pp |
| Q2 2025 | 2025-06-30 | −793.28% | +3550.96 pp |
| Q1 2025 | 2025-03-31 | −695.29% | +8785.91 pp |
| Q2 2024 | 2024-06-30 | −33,852.95% | −29030.44 pp |
| Q1 2024 | 2024-03-31 | −26,759.45% | −24147.52 pp |
| Q4 2023 | 2023-12-31 | −4,344.24% | −2913.45 pp |
| Q3 2023 | 2023-09-30 | −9,481.20% | −8391.50 pp |
| Q2 2023 | 2023-06-30 | −4,822.52% | +3666.15 pp |
| Q1 2023 | 2023-03-31 | −2,611.93% | +2869.48 pp |
| Q4 2022 | 2022-12-31 | −1,430.79% | +8360.12 pp |
| Q3 2022 | 2022-09-30 | −1,089.70% | +17450.04 pp |
| Q2 2022 | 2022-06-30 | −8,488.66% | −2359.35 pp |
| Q1 2022 | 2022-03-31 | −5,481.40% | +10117.33 pp |
| Q4 2021 | 2021-12-31 | −9,790.91% | −1838.28 pp |
| Q3 2021 | 2021-09-30 | −18,539.74% | −11653.04 pp |
| Q2 2021 | 2021-06-30 | −6,129.32% | +263.97 pp |
| Q1 2021 | 2021-03-31 | −15,598.74% | −11485.26 pp |
| Q4 2020 | 2020-12-31 | −7,952.62% | −5397.93 pp |
| Q3 2020 | 2020-09-30 | −6,886.71% | −4984.60 pp |
| Q2 2020 | 2020-06-30 | −6,393.28% | −3968.31 pp |
| Q1 2020 | 2020-03-31 | −4,113.47% | −1845.54 pp |
| Q4 2019 | 2019-12-31 | −2,554.70% | +1208.30 pp |
| Q3 2019 | 2019-09-30 | −1,902.10% | −119.14 pp |
| Q2 2019 | 2019-06-30 | −2,424.98% | −1673.56 pp |
| Q1 2019 | 2019-03-31 | −2,267.93% | −1903.09 pp |
| Q4 2018 | 2018-12-31 | −3,762.99% | −3139.43 pp |
| Q3 2018 | 2018-09-30 | −1,782.96% | −1333.31 pp |
| Q2 2018 | 2018-06-30 | −751.42% | −377.81 pp |
| Q1 2018 | 2018-03-31 | −364.84% | −57.64 pp |
| Q4 2017 | 2017-12-31 | −623.57% | +168.59 pp |
| Q3 2017 | 2017-09-30 | −449.65% | −140.95 pp |
| Q2 2017 | 2017-06-30 | −373.61% | −154.21 pp |
| Q1 2017 | 2017-03-31 | −307.20% | −161.96 pp |
| Q4 2016 | 2016-12-31 | −792.16% | +157.64 pp |
| Q3 2016 | 2016-09-30 | −308.70% | +119.70 pp |
| Q2 2016 | 2016-06-30 | −219.41% | +634.22 pp |
| Q1 2016 | 2016-03-31 | −145.24% | −142.46 pp |
| Q4 2015 | 2015-12-31 | −949.79% | — |
| Q3 2015 | 2015-09-30 | −428.39% | — |
| Q2 2015 | 2015-06-30 | −853.63% | — |
| Q1 2015 | 2015-03-31 | −2.78% | — |
Over the last five reported fiscal years, BioCorRx's operating margin increased from −6,109.86% to −606.04%, a change of +5503.82 percentage points. The latest reported quarter, Q2 2026, shows −1,665.95%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioCorRx filings at SEC.gov ↗